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ABSTRACT 
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive 
complex 2 and suppresses gene expression by catalyzing histone H3 methylation on lysine 27. 
EZH2 is overexpressed in metastatic prostate cancer and has been shown to promote cell 
proliferation and metastasis. Here we show that EZH2 also suppresses prostate cancer apoptosis 
by coordinating the epigenetic silencing of two pro-apoptotic microRNAs, miR-205 and miR-31.  
We previously reported that miR-205 is silenced in prostate cancer through promoter 
methylation. In this study, we found that EZH2 suppresses miR-31 expression by trimethylation 
of H3K27 on the miR-31 promoter. SiRNA knockdown of EZH2 increased miR-31 expression 
and decreased the anti-apoptotic protein E2F6 (a target of miR-31), resulting in the sensitization 
of prostate cancer cells to docetaxel-induced apoptosis and vice versa. We further demonstrated 
that miR-205 silencing is linked to miR-31 silencing through EZH2. Suppression of miR-205 
caused an increase of EZH2 protein, which in turn inhibited miR-31 expression and vice versa. 
Thus, EZH2 integrates the epigenetic silencing of miR-205 and miR-31 to confer resistance to 
chemotherapy-induced apoptosis.  
Besides the histone modification by histone methyltransferases (HMTs) such as EZH2, 
histone deacetylases (HDACs) offer another mechanism to epigenetically regulate gene 
expressions in cancer. The class I selective inhibitor of HDACs, mocetinostat, has promising 
antitumor activities in both preclinical studies and the clinical trials. To understand how 
mocetinostat induces apoptosis in prostate cancer cells, we examined the effects of mocetinostat 
on miR-31. We found that miR-31 was significantly upregulated by mocetinostat in prostate 
cancer cells. E2F6 was decreased by mocetinostat treatment. Mocetinostat also increased the 
expression of pro-apoptotic protein Bad and activated caspase-3 and caspase-9. SiRNA 
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knockdown of E2F6 sensitized cancer cells to mocetinostat-induced apoptosis. Importantly, we 
found the same results in the primary prostate cancer stem cells. Thus, activation of miR-31 and 
downregulation of E2F6 contribute to mocetinostat-induced apoptosis in prostate cancer.    
In summary, the epigenetic silencing of miR-31 confers a resistance mechanism for 
chemotherapy-induced apoptosis in prostate cancer cells. Using mocetinostat to activate miR-31 
expression is a novel strategy to overcome resistance to apoptosis and improve response to 
therapy. 
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CHAPTER 1. BACK GROUND INFORMATION; OBJECTIVES 
AND SPECIFIC AIMS; MATERIALS AND METHODS 
1.1. Back Ground Information 
1.1.1. Prostate Cancer 
Prostate cancer is a small walnut-shaped gland that is below the urinary bladder and in 
front of the rectum. Prostate cancer has the topmost incidence rate of new cancer cases in men in 
US. And it is the second leading cause of cancer related deaths in the developed world with 
increasing rates in developing world. In the United States in 2015, there were an estimated 
220,800 new cases of prostate cancer and about 27,540 deaths due to prostate cancer in men in 
the US (American Cancer Society, 2013-2014). The lifetime risk of developing prostate cancer is 
1 in 7 in men in the US (National Cancer Institute 2014). Prostate cancer is serious disease that 
may cause pain, difficulty in urinating, and problems during sexual intercourse, erectile 
dysfunction. However, most men diagnosed with prostate cancer do not die from it. In fact, more 
than 2.9 million American men are living with current or past diagnosis of prostate cancer.  
Prostate cancer starts in the cells of prostate gland. Actually, several types of cells are 
found in the prostate, but almost all prostate cancers develop from the gland cells (American 
cancer society 2010). Most prostate cancer cells tend to grow slowly compared with most other 
cancers, though there are cases of aggressive prostate cancers. The cells may begin to change 10, 
20, or even 30 years before a tumor is big enough to cause obvious symptoms. Eventually, the 
cancer cells may metastasize from the prostate to other parts of the body, particularly the bones 
and lymph nodes (National cancer institute). As cancer progresses, the tumor at the inner part of 
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the prostate (around the urethra) keeps growing; the prostate tissue can squeeze the urethra, 
leading to problems in passing urine (Figure 1). 
 
Figure 1. A normal prostate gland and a prostate with a tumor. (This figure is from Mayo 
foundation for medical education and research.) 
1.1.1.1. Prostate cancer risk factors  
A complete understanding of the causes of prostate cancer remains elusive (Hsing AW, 
Chokkalingam AP 2006). However the most probable cause is DNA mutations in cells. The 
DNA changes can pass down through families or occur due to environment or lifestyle. The 
demographic risk factors include age, genetics, and dietary and medication exposure. 
Age: The incidence of prostate cancer is strongly related to age, young age people can 
develop prostate cancer, but the incidence rate increases exponentially with advancing age. More 
than 80% of prostate tumors are diagnosed in men over 65. Men under 65 years of age vs. 65 
years and over, prostate cancer incidence rates were 56.8 vs. 974.7 per 100,000 person-year, 
respectively (Ries, L.A.G, M.P. Eisner 2003). 
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Genetics: Genetic background is associated with race, family, and specific gene variants 
that may contribute to prostate cancer risk. The risk of developing prostate cancer will be 
doubled in men who have a first-degree relative (father, brother, son) with prostate cancer, and 
five folded in men with two first-degree relatives (Steinberg GD, Carter BS 1990). In the United 
States, African American men are 60 percent (approximately) more likely to develop prostate 
cancer over their lifetime as compared to white or Hispanic men. African American men also 
have a higher motility rate (Hoffman RM, Gilliland FD 2001). 
Dietary: A diet high in saturated fat, as well as obesity, increases the risk of prostate 
cancer (Alexander DD, Mink 2010). While there are several evidences provided to demonstrate 
the role for dietary fruits and vegetables in prostate cancer incidence, however more research is 
needed to determine if this is a causative relationship (Key TJ 2011). 
1.1.1.2. Prostate cancer prevention    
The known risk factors of prostate cancer, age, race, and family history, can barely be 
controlled. Because of the exact cause of prostate cancer is still unknown, at this time there is no 
proven prostate cancer prevention strategy. Given that, there is no effective method for 
preventing prostate cancer, making healthy choices may help to lower the risk of prostate cancer. 
Limiting the consumption of animal products that contain trans fats, saturated fats, and 
carbohydrates is thought to reduce the risk of prostate cancer, though the evidence is 
inconclusive (Masko EM, Allott EH 2012). And Omega-3 fatty acid (commonly exists in fatty 
fish and flaxseed) has been linked to a reduced risk of prostate cancer (Heinze VM, Actis AB 
2012). Vitamin supplements have been studied and none of them are associated with lower risk 
of prostate cancer. Conversely, high intake of Calcium is correlated with advanced prostate 
cancer incidence (Datta M, Schwartz GG 2012). Besides the food and supplements, a medication 
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5-alpha-reductase inhibitor (Finasteride Proscar® and Dutasteride Avodart®) has shown a 
relative high degree of potential to reduce the overall risk of being diagnosed with prostate 
cancer. These drugs perform their role by impeding the formation of the most active form of 
testosterone that causes the prostate to grow. However, these drugs are still not approved by the 
FDA because of the insufficient data support to determine if they have an effect on the risk of 
death, and increased chance of more serious cases (Wilt TJ, MacDonald R 2008). 
1.1.1.3. Early detection of prostate cancer 
Due to the lack of reliable prevention strategies for prostate cancer, the early detection of 
prostate cancer is particularly important for the purpose of improving cure rate and reducing 
mortality. Screening is a common method that is utilized to detect a disease such as cancer in 
people who do not have obvious symptoms of that disease. For some types of cancer, screening 
can help to detect the warning signs of cancers at an early stage (American Cancer Satiety). 
Prostate cancer screening is testing to find unsuspected and asymptoms cancers, and may 
follow up with more invasive tests such as a biopsy. The screening methods of prostate cancers 
include Prostate-Specific Antigen (PSA) blood test and Digital Rectal Exam (DRE) (Djulbegovic 
M, Beyth RJ 2010). 
Prostate-Specific Antigen (PSA) blood test:  
Prostate-Specific Antigen blood test is to measure the concentration of PSA in blood to 
look for signs of prostate cancer and help to diagnose prostate cancer in its early stages, when 
treatment is more effective. PSA is a glycoprotein enzyme with folate hydrolase activity that is 
produced by epithelial cells in prostate gland. And it helps liquefy semen in the seminal 
coagulum to allow sperm to swim freely (Aumüller G 1979; Balk SP, Ko YJ 2003). PSA exists 
in both cancerous (malignant) and noncancerous (benign) prostate tissue. Usually cancer cells 
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have a higher level of PSA than noncancerous cells. A small amount of PSA secreted by prostate 
gland normally can enter the bloodstream, and a level of less than 4 ng/ml (nanograms per 
milliliter) PSA blood concentration is regarded as normal. But the causes of elevating PSA levels 
in blood can also be a noncancerous condition such as prostatitis or an enlarged prostate. 
Therefore, PSA is not a unique indicator of prostate cancer and determining what a high PSA 
score means can be complicated (Velonas VM, Woo HH 2013). 
Digital Rectal Exam (DRE): 
A digital rectal exam is another screening test for prostate cancer early detection. As part 
of a complete physical examination, DRE is to check for growths in or enlargement of the 
prostate gland (WebMD.com). Since prostate is an internal organ that lies in front of the rectum, 
the exam is performed by inserting a lubricated, gloved finger into the rectum, and use another 
hand to press on the lower belly or pelvic area to feel for lumps, soft or hard spots, and other 
abnormalities. To minimize the risk of misdiagnosing prostate cancer, DRE should always be 
done with a PSA test (Fritz H. Schröder, Jonas Hugosson 2009). 
Prostate biopsy and Gleason Score: 
If the result from a PSA blood test rises to a level that prostate cancer is suspected to 
occur or the result from a DRE finds abnormality, prostate biopsy will be advisable for the 
patient to be performed. Prostate biopsy is a series of procedures that are performed to remove 
small hollow needle-core samples from a man’s prostate gland. And the collected tissue samples 
are examined for the presence of cancer cells under microscope (Essink-Bot ML, de Koning HJ 
1998-06-17). 
Gleason score is used to help evaluate the microscopic features of biopsy cylindrical 
samples and incorporated into the strategy of prostate cancer staging that predicts prognosis and 
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helps guide therapy. A Gleason score is given to prostate cancer depended on its microscopic 
appearance. Lower scores are associated with small, closely packed glands. And as the score 
increases, cells exhibit a spread out pattern and start lose their glandular architecture (“Male 
Genital Pathology” 2009-05-13). Gleason scores range from 2 to 10, with 2 representing the 
most well differentiated tumors and 10 the least-differentiated tumors (Kumar V, Abbas AK 
2004). Gleason score, PSA, and DRE work together to determine clinical risk, which then 
dictates treatment option (Epstein JI, Allsbrook WC Jr 2005; 29(9): 1228-42). 
1.1.1.4. Prostate cancer treatment (American Cancer Society)  
There are different types of treatment options for prostate cancer. And the choices doctors 
make depend on several factors, which include how widely it has spread and patients’ overall 
health, as well as the benefits and the potential side effects of the treatment (Mayo clinic). 
Typically seven standard treatments are used: Watchful waiting or active surveillance, surgery, 
radiation therapy, hormone therapy, chemotherapy, biologic therapy and bisphosphonate therapy. 
In addition to these, three new types of treatment are being tested in clinical trials: Cryosurgery, 
high-intensity focused ultrasound and proton beam radiation therapy. 
1.1.2. Epigenetics  
Epigenetics refers to changes in gene expression via covalent chemical modifications of 
DNA, associated proteins, or RNA, resulting in changes to the function and/or regulation of 
these molecules, without an alteration in their primary sequence (Vichithra R. B. Liyanage, 
Jessica S. Jarmasz 2013). The epigenetic changes comprise DNA methylation, histone 
modification, nucleosome remodeling and RNA-associated silencing (Costantine Albany, Ajjai 
S. Alva 2011). These changes lead to conformational transforms in the DNA double helix and 
chromatin packaging. And eventually, these changes impact the transcription of associated genes 
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by modifying the access of transcription factors to promoter regions upstream of coding 
sequences (D. Hanahan, R.A. Weinberg, 2011; A. S. Perry, R.W.G. Watson 2010). Epigenetic 
mechanisms are crucial for normal development and maintenance of tissue-specific gene 
expression patterns in mammals (Shikhar Sharma, Theresa K.Kelly 2010). Progressive 
epigenetic aberrations can exert profound outcomes such as gene function alteration and 
malignant cellular transformation. Global changes in the epigenetics contribute as a hallmark in 
initiation and progression of cancer (Shikhar Sharma, Theresa K. Kelly 2010). 
1.1.2.1. DNA methylation 
DNA methylation is a covalent biochemical modification process where a methyl group 
is enzymatically added to the carbon-5 position of the cytosine ring (P. M. Das, R. Singal 2004). 
And this modification can give rise to a spontaneous deamination of 5-methylcytosine to 
thymine, consequently cause conformational changes of chromatin and transcriptional 
suppression (A. P. Bird, 1986). (Figure 2) The sequence 5’-CG-3’ (also called the CpG 
dinucleotide) is the most favorable substrate for DNMTs. In adult genome, 60-90% of CpG 
dinucleotides are methylated. The unmethylated CpG dinucleotides are usually present on the 
region of DNA in normal tissues, especially on promoter region, which are called CpG islands. 
CpG islands are regions with a high frequency of CpG sites, usually defined as a sequence with 
at least 200bp, and a CG content percentage larger than 50%, and with an observed to expected 
ratio of CpG that is more than 60% (D. Takai and P.A. Jones 2002). The DNA methylation is 
accomplished by three identified DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) 
that present a higher affinity to 5-methylcytosine than to cytosine, and lead to functional 
silencing of gene expression (M. Manoharan, K. Ramachandran 2007). (Figure 3) 
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Figure 2. DNA methylation causes conformational changes of chromatin. DNA methylation adds 
a methyl group to the carbon-5 position of the cytosine ring by DNMT, then spontaneously 
deaminates to thymine in genomes. (This figure is from Scarano E., Laccarino M, et al., 1967.) 
 
 
Figure 3. Epigenetics of gene expression silencing. (a) In unmethylated DNA (depicted by white 
hollow circles on left) transcription factors (TF) can easily access the gene promoter regions. In 
hypermethylated DNA (depicted in red filled-in circles on the right) access of TF to gene promoter 
regions is sterically hindered resulting in functional silencing of gene expression. (b) The 
methyl-CpG-binding domain protein (MPD)/histone deacetylase (HDAC) complexes can 
enzymatically cause histone deacetylation, which is associated with a condensed structure that 
inhibits normal gene transcription. (This figure is from M. Manoharan, K. Ramachandran, et al., 
2007.)    
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1.1.2.2. DNA methylation in prostate cancer  
To acquire and maintain the neoplastic phenotype of prostate cancer, the promoters are 
commonly hypermethylated. In prostate cancer, several classic tumor-suppressor gene functions 
are repressed by hypermethylation, which include hormone signaling, DNA repair, cell adhesion, 
cell-cycle control, and apoptosis (S. Yegnasubramanian, J. Kowalski 2004; C. Jeronimo, R. 
Henrique 2004; R. Maruyama, S. Toyooka 2002). (Table 1) Hypomethylation, a second 
methylation defect, is commonly observed in advanced stage prostate cancer and contributes to 
oncogenesis. A number of mechanisms of hypomethylation are applied for cancer occurrence, 
such as activation of oncogenes (c-MYC and H-RAS), activation of latent retrotransposons, and  
Table 1. Hypermethylated genes in prostate cancer. (This table is from S. Yegnasubramanian, J. 
Kowalski 2004.) 
DNA repair gene 
GSTP1  
MGMT 
Tumor-suppressr genes 
APC 
RARβ 
RASSF1 
Hormone receptor genes 
AR 
ESR1,2 
Cell adhesion genes 
CDH1 
CDH13 
CDH4 
Cell-cycle control genes 
CCDN2 
CDKN1B 
SFN 
Apoptotic genes 
GADD45a 
PYCARD 
RPRM 
GLIPR1 
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reduction of chromosome stability (W. G. Nelson, S. Yegnasubramanian, 2007; S. 
Yegnasubramanian, M. C. Haffner 2008). 
1.1.2.3. Histone modification and chromatin remodeling  
The nucleosome is the fundamental repeating units of eukaryotic chromatin, which 
consists of approximately 174bp of DNA tightly wrapped almost two times around the 
cylindrical histone octamer. Histone octamer composed of two copies of each of the four core 
histone proteins (Alberts Bruce 2002). Histone proteins are classified as either core histones 
(H2A, H2B, H3, and H4) or linker histones (H1 and H5) (Cox Michael, Nelson David R. 2005; 
Bhasin M, Reinherz EL, Reche PA 2006; Hartl Daniel L., Freifelder David 1988). Histones are 
not only enable packaging of the large genome into nucleus, but also realized as being dynamic 
regulators of gene activity that undergo many posttranslational chemical modifications, including 
methylation, acetylation, ubiquitination, and phosphorylation (M. Esteller 2007). The 
modifications commonly occurr on the N-terminal tails of core histones that are rich in positively 
charged amino acids, which protrude out of the nucleosome. (Table 2) Three prominent 
regulators of histone modification are histone deacetylases (HDACs), histone acetyltransferases 
(HATs), and histone methyltransferases (HMTs) (J. R. Dobosy and E. U. Selker 2001; M. H. 
Kuo and C. D. Allis 1998). Different modifications are likely to result in either gene activation or 
suppression that depends on the amino acid position and the number of added residues (C. 
Martin and Y. Zhang 2005; T. Kouzarides 2007). (Table 3) Although the biological significance 
of histone modifications is still elusive, these modifications are known to be involved in diverse 
biological processes including DNA repair, gene regulation, spermatogenesis (meiosis) and 
chromosome condensation (mitosis) (Ning Song, Jie Liu 2011). 
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Table 2. Types of histone modifications (This table is from Kouzarides T. 2007) 
Amino Acid Modification 
Lysine Methylation, 
Acetylation, 
Ubiquitination, 
Sumoylation, 
ADP-Ribosylation 
Arginine Methylation 
Serine Phosphorylation 
Threonine Phosphorylation 
 
Table 3. “Histone codes”, combination of histone modifications in transcription regulation. 
(This table is from Strahl BD, Allis CD 2000; Jenuwein T, Allis CD 2001.) 
Type of 
modification 
Histone 
H3K4 H3K9 H3K14 H3K27 H3K79 H3K36 H4K20 H2BK5 
Mono-methyl
ation 
activat
ion 
activati
on 
 
activati
on 
activati
on 
 
activati
on 
activati
on 
di-methylaton  
repressi
on 
 
repressi
on 
Activati
on 
 
   
tri-methylatio
n 
activat
ion 
repressi
on 
 
repressi
on 
Activati
on 
repressi
on 
activati
on 
 
repressi
on 
acetlyation  
activati
on 
activati
on 
activati
on 
    
 
1.1.2.4. Histone modification in prostate cancer 
Increasing evidence indicates that histone modification has a crucial role in prostate 
tumorigenesis. The predictable clinical outcomes of different change levels in individual histone 
modifications can help to identify patients with adverse prognosis and high risk for recurrence (J. 
Ellinger, P. Kahl 2010; T.Bianco-Miotto; K. Chiam 2010). For instance, global methylation of 
H3K4 and acetylation of H3K18Ac can refer to the independent predictor of recurrence in 
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low-grade prostate cancer (D. B. Seligson, S. Horvath 2005; L. X. Zhou; T. Li 2010). Histone 
methyltransferase, EZH2 (Enhancer of zeste homolog 2) was shown to be amplified and 
overexpressed in a variety of cancers including prostate cancer (Chase A, Cross NC. 2011). High 
level expression of EZH2 has shown to be closely correlated with prostate cancer progression. 
Moreover, the increase of EZH2 expression is recognized as a predictor of a higher risk of 
recurrence after radical prostatectomy (Varambally S., Dhanasekaran SM 2002; Berezovska OP, 
Flinskii AB 2006). EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2). 
It suppresses gene expression by catalyzing the trimethylation of lysine 27 on histone 3 (H3K27) 
(Cao R., Wang L. 2008). (Figure 4) PRC2 can catalyze sequential methylation at H3K27, 
producing mono-, di-, and trimethylated H3K27 (H3K27me1, H3K27me2, and H3K27me3) 
(Simon JA, Lange CA. 2008). The PRC2 complex contains five subunits, including EZH2, EED, 
SUZ12, RbAp46/48, and AEBP2. The oncogenic activity of EZH2 has been extensively studied 
in prostate cancer and most results are focusing on its function in promoting proliferation and 
metastasis (Kleer CG, Cao Q. 2003; Bachmann IM, Halvorsen OJ 2006; Deb G., Thakur VS 
2013; Velichutina I., Shaknovich R. 2010; Cao Q., Yu J. 2008). Recent studies have also 
demonstrated that EZH2 can suppress apoptosis (Q Zhang, SKR Padi 2014). However, the 
mechanisms of apoptosis suppression by EZH2 remain poorly understood. 
 
Figure 4. The mutation of EZH2 usually turns on gene transcription. (This figure is from 
Costantine Albany, Ajjai S. Alva 2011.) 
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1.1.2.5. Epigenetic therapy of cancer 
Unlike the classic genetic alterations that encode information within the DNA sequence, 
epigenetic changes can store the information in multiple dimensions, such as in the form of DNA 
modifications, histone modifications, or RNA silencing. The multidimensional nature of 
epigenetics provides many and varied potentials for medical applications (Chahwan R, Wontakal 
SN, Roa S. 2011). Epigenetic therapy aims to use drugs or other epigenome-influencing 
techniques to reverse the abnormal epigenetic changes in cancer to treat medical conditions.  
Table 4. FDA-Approved epigenetic therapies (This table is from Jane de Lartigue 2013.) 
Agent Class Company 
Approval 
Date 
Approved Indication 
Azacitidine 
(Vidaza) 
DNMT 
inhibitor 
Celgene 
Corportation 
2004 
FBA myelodysplastc 
syndrome subtypes 
Decitabine 
(Dacogen) 
DNMT 
inhibitor 
Eisai 2006 Myelodysplastic syndrome 
Vorinostat 
(Zolinza) 
Pan-HDAC 
inhibitor 
Merck 2006 Cutaneous T-cell lymphoma 
Romidepsin 
(Isodax) 
Class I HDAC 
inhibitor 
Celgene 
Corportation 
2009 Cutaneous T-cell lymphoma 
Ruxolitinib 
(Jakafi) 
JAK1/2 
inhibitor 
Incyte 
Pharmaceuticals 
2011 
Intermediate or highrisk 
myeofibrosis 
 
Azacytidine and Deoxyazacytidine are discovered as two DNA methyltransferase 
inhibitors. They have already been approved by the Food and Drug Administration (FDA) to 
treat patients with myelodysplastic syndromes, a blood cancer produced by abnormal bone 
marrow stem cells (Jones PA, Baylin SB 2002). An inhibitor of histone deacetylase, Vorinostat 
(Suberoylanilide hydroxamic acid), has also been approved for the treatment of cutaneous T-cell 
lymphoma. (Table 4) In addition to DNA methylation and HDAC inhibitors, 3-Deazaneplanocin 
A (DZNep), which is a histone methyltransferase (HMT) inhibitor, has also been developed to 
target the degradation of histone methyltransferase EZH2 and then selectively inhibit 
trimethylation of H3K27me3 and H4K20me3 as well as reactive silenced genes in cancer cells 
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(Miranda TB, Cortez CC 2009). Other epigenetics drugs with diverse targets are in clinical trials 
or development as well.  
1.1.3. Mocetinostat (MGCD): Class I Selective HDAC Inhibitor 
Histone deacetylases (HDACs) are important epigenetic regulators of gene expression 
(Gray S.G. and T.J. Ekstrom 2001). These enzymes deacetylate lysines of core histone tail and 
result in transcription repression (Strahl B.D. C.D. Allis 2000). HDACs also deacetylate lysines 
of other proteins and regulate cellular functions ranging from proliferation, apoptosis, to 
metastasis and angiogenesis (Minucci S. and P.G. Pelicci 2006; Choudhary C., et al. 2009). 
There are eighteen mammalian HDACs and they are classified into four groups (Haberland M., 
R.L. Montgomery 2009): class I HDACs (HDAC1, -2, -3, and -8); class II HDACs (HDAC4, -5, 
-6, -7, -9, and -10); class III HDACs (sirt1-7); and class IV HDAC (HDAC11). The class I 
HDACs are frequently upregulated in various types of cancers compared to the corresponding 
normal tissues and their upregulation is associated with a poor prognosis (Weichert W., et al. 
2008. 9(2): p.138-48; Weichert W., et al. 2008. 98(3):p.604-10; Weichert W., et al. 2008. 
14(6):p.1669-77). HDAC inhibitors have been developed and extensively tested in phase I–III 
clinical trials. However, these new agents showed minimal clinical activity in patients with solid 
tumors while undesired side effects are also a problem (Slingerland M., H.J. Guchelaar 2014).  
One of the reasons for the poor performance of the early generation of HDAC inhibitors may be 
because they inhibit multiple classes of HDACs, which results in toxicity and limits the 
achievable therapeutic doses. Mocetinostat, also known as MGCD0103, is one of the new class I 
selective HDAC inhibitors (Fournel M., et al. 2008). Preclinical studies have demonstrated 
broad-spectrum antitumor activities of mocetinostat against various types of cultured cell lines 
and tumor xenografts in nude mice (Fournel M., et al. 2008; Bonfils C., et al. 2008). It has been 
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shown that mocetinostat inhibits colon cancer cell growth by upregulating WNT ligand DKK-1 
expression (Sikandar S., et al. 2010). In B-cell chronic lymphocytic leukemia cells, mocetinostat 
has been shown to induce apoptosis through decreasing anti-apoptotic Mcl-1 protein and 
inducing Bax translocation to the mitochondria (El-Khoury V., et al. 2010). While mocetinostat 
has been shown to effectively kill prostate cancer cells (Fournel M., et al. 2008), the mechanisms 
of apoptosis induction remain poorly understood. 
1.1.4. Noncoding MicroRNAs 
MicroRNAs (microRNAs) are small non-coding RNAs with a length of about 22 
nucleotides. Commonly, microRNAs genes are transcribed by RNA Polymerase II (Pol II) to 
form large ~80-nucleotide-long primary microRNAs with a hairpin structure. The primary 
microRNAs are processed by the ribonuclease Drosha and RNA binding protein Pasha to 
become 60-70 nucleotide-long precursor microRNAs. Following that, the enzyme Ran 
GTP/Exportin 5 exports the precursor microRNAs out of nucleus. In cytoplasm, the precursor 
microRNAs are further processed into 19-25 nucleotides long mature microRNAs by the RNase 
III protein Dicer. The mature microRNAs are incorporated into the RNA-induced silencing 
complex (RISC) to interact with target mRNAs and associate with the 3’-untranslated region 
(UTR). Eventually the interaction causes either degradation of mRNA or translational repression 
to regulate gene expression depending on the degree of complementarity (Bartel DP 2009; Lee 
y., et al 2002; Cai X., et al., 2004). (Figure 5) 
MicroRNAs regulate very extensive biological functions and processes in plant and 
animals. In human, around 2000 microRNAs have been discovered, and individual microRNA 
targets about 100 to 200 messenger RNAs (Lim L., Lau N. 2005). Approximately 60% human 
protein-encoding genes are modulated by microRNAs at the level of transcription or translation 
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into proteins (Friedman R, Farh K 2009). Many microRNAs themselves are controlled by 
epigenetic changes including DNA methylation and histone modification or the combination of 
both (Bernal J, Duran C 2012). Dysregulation of various microRNAs has been shown to play 
critical roles in cancer biology, ranging from proliferation (Kota J, Chivukula RR 2009), 
differentiation (Chen CZ, Li L. 2004; Zhang J, Jima DD 2009), metabolism (Poy MN, Eliasson L 
2004), metastasis (Ma L, Teruya-Feldstein J 2007), to apoptosis (Hermeking H. 2010). 
MicroRNAs have been reported to be potential targets for epigenetic therapy. By mimicking 
tumor suppressor microRNAs, treatment based microRNAs can be synthesized to selectively 
repress oncogenes in tumors and restore normal microRNA-mRNA regulation pathways. The 
challenge of this novel therapeutic strategy is to establish a safe and efficient deliver system to 
introduce synthetic microRNAs to tumor cells (Shikhar Sharma, Theresa K. Kelly 2010). 
 
Figure 5. Biogenesis of microRNAs. (This figure is from Nat Rev Cancer 2010 Nature Publishing 
Group.) 
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1.2. Objective and Specific Aims 
1.2.1. Objective of the Study (Project 1) 
The main goal of this project was to investigate the novel epigenetic mechanisms of 
apoptosis regulation in prostate cancer.  
Prostate cancer has the top incidence rate of new cancer cases, and it is the second 
leading cause of cancer-related death in the United States. The histone methyltransferase EZH2 
has been reported to significantly overexpress in metastatic prostate cancer. High levels of EZH2 
expression correlates with prostate cancer progression and a higher risk of recurrence after 
radical prostatectomy. Recent studies have also demonstrated that EZH2 can suppress apoptosis. 
However, the mechanisms of apoptosis suppression by EZH2 remain poorly understood. We 
have focused on the novel epigenetic mechanisms of apoptosis regulation in prostate cancer. 
MiR-31 is one of the most downregulated miRNAs in advanced prostate cancer cells. We 
identified that EZH2 is potentially responsible for the downregulation of miR-31. The 
antiapoptotic protein E2F6 (target of miR-31) downregulation is related to sensitize prostate 
cancer cells to docetaxel-induced apoptosis. Also, it has been recently reported that miR-205 can 
decrease the expression of EZH2 protein in prostate cancer. By silencing of miR-205, we have 
shown that the expression of EZH2 is upregulated, which in turn epigenetically represses miR-31 
expression. 
This study is important because the results will help us to understand the epigenetic 
mechanism of EZH2 regulation of apoptosis in prostate cancer.  
Various small-molecule drugs have been developed to target EZH2, including EI1, GSK 
126, DZNep and UNC1999. For instance, GSK 126 is a very potent EZH2 inhibitor (with a Ki of 
0.5-3nM) and has high selectivity for EZH2 (more than 1000-fold higher activity than its activity 
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for 20 other human methyltranserases). And it is known that EZH2 inhibitors have significant 
anti-cancer properties by inducing apoptosis to suppress tumor growth and increase survival 
(McCabe MT, Ott HM 2012; Tan J Yang X 2007; Knutson SK, Wigle TJ 2012). However, the 
mechanisms of EZH2 in apoptosis regulation remain elusive.  
This study has the potential to identify a new mechanism for EZH2 suppression of 
apoptosis in prostate cancer. Our study is innovative because the mechanism for 
miR-31downregulation in prostate cancer has never been investigated and the role of EZH2 in 
apoptosis regulation in prostate cancer is entirely novel. As a new epigenetic mechanism to 
regulate apoptosis, the axis of miR-205, miR-31 and EZH2 will provide a conceptual advance in 
cancer response to chemotherapy. 
In this study, we hypothesize that EZH2 coordinates the silencing of the proapoptotic 
miR-205 and miR-31 to confer resistance to chemotherapy-induced apoptosis in prostate cancer. 
1.2.2. Specific Aims (Project 1) 
To test our hypothesis, the following specific aims were proposed: 
i) To determine the mechanism of downregulation of miR-205 and miR-31 in prostate 
cancer in vitro.     
The working hypothesis was that DNA methylation-mediated silencing of miR-205 can 
lead to histone methylation-mediated silencing of miR-31, with EZH2 as the coordinator of the 
two separate events. As a result, the expression of antiapoptotic protein E2F6 is increased and 
contributes to the development of apoptosis resistance. The experimental design for this part of 
the study was:  
a) To determine the effect of EZH2 on miR-31expression in prostate cancer cells by  
Western blot and real-time PCR analysis. 
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b) To determine the mechanism by which miR-31 is downregulated by EZH2 with 
chromatin  
immunoprecipitation assay. 
c) To determine the effect on EZH2 on docetaxel-induced apoptosis in prostate cancer  
cells by cell death ELISA plus assay. 
d) To determine the effect of E2F6 on chemotherapy-induced apoptosis in prostate 
cancer cells by cell death Elisa plus assay. 
e) To determine the effect of miR-205 on EZH2 regulated miR-31 in prostate cancer  
cells. 
ii) To determine the expression and regulation of miR-205, EZH2, and miR-31 in human 
prostate cancer specimens.  
The working hypothesis was that miR-205 and miR-31 expression levels will be 
decreased in the cancer samples compared with the adjacent normal tissues. In the meantime, 
EZH2 expression will be upregulated in the cancer specimens. The experimental design for this 
part of the study was: 
a) To determine the expression levels of miR-205 and correlation with EZH2 expression 
in human prostate cancer specimens by Real-Time PCR.  
b) To determine the expression levels of miR-31 and correlation with EZH2 expression 
in human prostate cancer specimens by Real-Time PCR.  
1.2.3. Objective of the Study (Project 2) 
The main goal of this project was to investigate the mechanisms how mocetinostat 
induces apoptosis in prostate cancer.  
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Histone deacetylases (HDACs) are important epigenetic regulators of gene expression. 
Mocetinostat is a class I selective HDAC inhibitor and has promising antitumor activities in 
preclinical studies. Recent clinical trials have demonstrated excellent response of mocetinostat 
against myelodysplastic syndrome and relapsed Hodgkin's lymphoma. However, a phase II study 
also found that mocetinostat has limited efficacy as a single agent in relapsed and refractory 
chronic lymphocytic leukemia (CLL). Thus, it is important to understand the mechanism of 
mocetinostat-induced apoptosis in order to improve its efficacy in cancer therapy and overcome 
drug resistance.  
This study has the potential to provide an insight mechanism of mocetinostat to exert 
antitumor activities by inducing apoptosis in prostate cancer. Our study is innovative because 
this is the first study of microRNAs in the antitumor action of mocetinostat. The axis of miR-31 
and its target E2F6 is a novel mechanism to elucidate the apoptosis-inducing function of 
mocetinostat. 
In this study, we hypothesize that activation of miR31 and downregulation of E2F6 
contribute to mocetinostat-induced apoptosis in prostate cancer cells. 
1.2.4. Specific Aims (Project 2) 
To test our hypothesis, following specific aims were proposed: 
i) To determine the role of mocetinostat on proapoptotic miR-31 expression in prostate 
cancer in vitro.     
a) To determine if mocetinostat can induce apoptosis in prostate cancer by crystal violet 
assay. 
b) To determine the effect of mocetinostat on miR-31 expression by selectively inhibiting 
the class I HDACs in prostate cancer using cell death Elisa plus assay. 
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c) To determine the expression status of activate caspases by western blot analysis. 
d) To determine the effect of E2F6 on mocetinostat-induced apoptosis in prostate cancer 
cells by cell death Elisa plus assay. 
ii) To determine the role of mocetinostat on proapoptotic miR-31 expression in primary 
prostate cancer stem cells.    
a) To determine if mocetinostat can inducemiR-31 expression and activates apoptosis in 
primary prostate cancer stem cells. 
1.3. Materials and Methods 
1.3.1. Cell Lines Used and Transfection 
The prostate cancer cell lines WPE1-NA22, PC-3, and DU-145 were obtained from 
American Type Culture Collection (Manassas, VA, USA). The WPE1-NA22 cells were cultured 
in Keratinocyte Serum Free Medium (K-SFM, Invitrogen), supplemented with bovine pituitary 
extract and human recombinant epidermal growth factor. PC-3 and DU-145 cells were cultured 
in RPMI-1640 medium (Hyclone, Thermo scientific) containing 10% fetal bovine serum (FBS). 
All cell lines were maintained in 5% CO2-humidified atmosphere at 37℃, and passaged using 
0.05% trypsin-EDTA (Invitrogen). Human prostate cancer stem cells were purchased from 
CELPROGEN (San Pedro, CA) and cultured following the manufacturer’s protocol. For 
transient transfection, plasmids were transfected into cells using LipofectamineTMPlus Reagent 
(Invitrogen) following the manufacturer’s protocol. SiRNAs were transfected into cells using 
X-treme GENE siRNA transfection reagent (Roche) following the manufacturer’s protocol. 
1.3.2. Drugs and Chemicals  
Docetaxel was purchased from Sigma. 3-Deazaneplanocin A (DZNep CAS 102052-95-9) 
was purchased from Cayman Chemical Company. Formaldehyde was purchased from Alfa 
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Aesar (Ward Hill, MA). Mocetinostat was purchased from Selleckchem (Houston, TX). 
Vorinostat was purchased from Biovision (Mountain View, CA).    
1.3.3. Western Blot Analysis 
Cells were lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS in 
PBS). Complete protease inhibitor cocktail (Roche) was added to lysis buffer before use. Protein 
concentration was determined by Bio-Rad DC protein assay kit (Bio-Rad). Protein samples were 
subjected to SDS-PAGE and transferred to nitrocellulose membranes (Millipore). The 
membranes were blocked with 5% non-fat milk in PBS overnight at 4℃ then incubated with 
primary antibody and subsequently with appropriate horse radish peroxidase-conjugated 
secondary antibody. The protein bands were developed with ECL reagents (Pierce) and exposure 
to X-ray films. Anti-β-tubulin and anti-E2F6 antibodies were purchased from Santa Cruz 
Biotechnology. Cleaved caspase-9, cleaved caspase-3, cleaved PARP, Bad, Bid, Bak, Puma, Bax, 
and EZH2 antibodies were purchased from Cell Signaling. 
1.3.4. Detection of Apoptosis by Cell Death Assay ElisaPLUS 
The Cell Death Detection ElisaPLUS kit (Roche) was used to detect apoptosis following 
the manufacturer’s protocol. This assay determines apoptosis by measuring mono- and 
oligonucleosomes in the lysates of apoptotic cells. The cell lysates were placed into a 
streptavidin-coated microplate and incubated with a mixture of anti-histone-biotin and 
anti-DNA-peroxidase antibodies, and incubation buffer for two hours. The antibodies were 
bound to the histone- and DNA-component of the nucleosomes, and the immunocomplexes were 
fixed to the microplate by streptavidin-biotin interaction. The amount of peroxidase retained in 
the immunocomplex was photometrically determined with ABTS as the substrate. Absorbance 
was measured at 405 nm. 
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1.3.5. WST-1 Cell Proliferation Assay 
WST-1 reagent (Roche, Indianapolis, IN) is a simple, colorimetric assay designed to 
measure the relative proliferation rates of cells in culture medium. The principle of WST-1 assay 
is based on the conversion of the tetrazolium salt, WST-1 (slightly red) into water soluble 
formazan dye (dark red) by mitochondrial dehydrogenase present only in viable cells. The 
activity of mitochondrial dehydrogenase increases proportionally to the number of viable cells, 
leading to an increase in the conversion of WST-1 to formazan dye. The resulting increased color 
intensity is in turn quantified by measuring the absorbance at 440 nm wavelength. Procedure in 
brief, after treatment with Docetaxel, prostate cancer cells were incubated with WST-1 for 4 
hours at 37o C in a humidified atmosphere maintained at 5 % CO2 as recommended by the 
manufacturer. The absorbance of the formazan dye was measured colorimetrically. 
1.3.6. Real-Time Polymerase Chain Reaction 
Gene expression was measured by real-time PCR using TaqMan® assays (Cat # TM509 
for miR205, TM1100 for miR-31, Hs00544833_m1 for EZH2) from Applied Biosystems (Foster 
city, CA). Total RNA was isolated using mirVana™ miRNA Isolation Kit (Ambion) according 
to the manufacturer’s instructions and quantified with a Nano-Drop spectrophotometer. 5μg of 
total RNA was used in the reverse transcription reaction. The cDNAs were used as templates to 
perform PCR on an Applied Biosystems 7500 Real-time PCR System following the 
manufacturer’s protocol. Relative miRNA expression levels were calculated using 18S RNA as 
reference. 
1.3.7. 5’ RACE 
The transcription start site of miR-31 pri-miRNA was identified by 5’RACE experiments 
with FirstChoice® RLM-RACE kit from Ambion, using total RNA isolated from WPE1-NA22 
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cells as template. cDNA was synthesized from total RNA (5 µg) with random primers. The 5’ 
ends of the miRNAs were amplified with a gene-specific primer. Amplicons were reamplified 
successively with nested-gene-specific primers. 
1.3.8. Transient Transfection of PC-3 Cells with pCEP4-EZH2 Plasmid 
We created an expression vector to over express the full length EZH2 gene in PC-3 cells. 
The EZH2 cDNA was cloned into the pCEP4 vector (Figure 6) to express EZH2 as a Flag-tagged 
protein. Full length EZH2 gene was obtained by polymerase chain reaction (PCR) using 
expressed-sequence tag (EST) clone as a template. Transient transfection was done in PC-3 cells 
with this plasmid using Lipofectamine TM PLUS Reagent (Invitrogen) following manufacturer’s 
protocol. 1.0 μg/ml of plasmid was used to form complexes with transfection reagent. EZH2 
overexpression was confirmed by western blot using anti-Flag antibody. 
                
Figure 6. pCEP4 plasmid. (Invitrogen Catalog # V044-50). 
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1.3.9. Transient Transfection of PC-3 Cells and DU-145 Cells with Negative Control or 
EZH2 SiRNA 
The Silencer® siRNAs for EZH2 (target sequence GACUCUGAAUGCAGUUGCU) and 
negative control (Catalog # AM4611) were purchased from Ambion. These siRNAs were 
transfected into PC-3 cells and DU-145 cells using X-tremeGENE siRNA transfection reagent 
(Roche, Indianspolis, IN) following manufacturer’s protocol. 100 nM negative control or EZH2 
siRNA was used for transfection into PC-3/DU-145 cells and EZH2 knockdown was confirmed 
by western-blot. Effect of EZH2 knockdown on drug resistance was determined by Cell Death 
Elisa Assay.  
1.3.10. Transient Transfection of PC-3 Cells with Negative Control or E2F6 SiRNAs  
 The Silencer® siRNAs for E2F6 (siRNA ID 4185) and negative control (Catalog # 
AM4611) were purchased from Ambion. These siRNAs were transfected into PC-3 cells using 
X-tremeGENE siRNA transfection reagent (Roche, Indianspolis, IN) following manufacturer’s 
protocol. 100 nM negative control or E2F6 siRNA was used for transfection into PC-3 cells and 
E2F6 knockdown was confirmed by western-blot. Effect of E2F6 knockdown on drug resistance 
was determined by Cell Death Elisa Assay.  
1.3.11. Transient Transfection of PC-3 Cells with MiR-205 and MiR-NC Mimics 
miRIDIAN® miR-205 mimic (Cat# C-300564-05) and negative control miRNA (Cat# 
CN-001000-01-05) were purchased from Dharmacon. miRIDIAN® Pre-miR™ miRNA 
Precursor Molecules are small, chemically modified, double-stranded RNA molecules designed 
to mimic endogenous mature miRNAs. These miRNA mimics were transfected into PC-3 cells 
using X-tremeGENE siRNA transfection reagent (Roche, Indianapolis, IN) following 
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manufacturer’s protocol. 100 nM negative control miRNA or miR-205 mimic was used for 
transfection into PC-3 cells and the effect of transfection was confirmed by western blot analysis. 
1.3.12. Transient Transfection of PC-3 Cells with Anti-miRTM Inhibitor for MiR-205  
Anti-miRTM microRNA Inhibitor for miR-205 (ID AM11015) was purchased from Life 
Technologies.  Anti-miRTM microRNA Inhibitors are ideal for use as specific suppressors of 
microRNA activity. These miRNA inhibitors were transfected into PC-3 cells using 
X-tremeGENE siRNA transfection reagent (Roche, Indianapolis, IN) following the 
manufacturer’s protocol. 100 nM Anti-miRTM microRNA inhibitor specific to miR-205 or the 
negative control inhibitor was used for transfection. Total RNA and protein was isolated to 
analyze the miR-31 and EZH2 / E2F6 expression by RT-PCR and Western blot respectively. 
1.3.13. Plasmid Construction 
The full-length E2F6 cDNA was obtained by PCR using an EST clone as template and 
constructed into pcDNA3-HA vector. 
1.3.14. Chromatin Immunoprecipitation Assay 
Chromatin immunoprecipitation (ChIP) assay was performed using the ChIP assay kit 
from Millipore (Billerica, MA, USA). Formaldehyde was added directly to the medium 
containing prostate cancer cells after desired DZNep treatment (5μM) or SiRNA knockdown of 
EZH2, to crosslink histones to DNA. After incubating cells with formaldehyde for 10 minutes at 
370C and 5% CO2, media was removed as much as possible. Cells were washed twice using ice 
cold PBS containing protease inhibitors. Cells were scrapped into a conical tube and centrifuged 
at 2000 rpm for 4 minutes at 40C. Cell pellet was resuspended in 200μl of SDS Lysis Buffer with 
protease inhibitors and incubated for 10 minutes on ice. (200μl of SDS Lysis Buffer is per 1 X 
106 cells, the resuspended cell pellet should be divided into 200μl aliquots so that each 200μl 
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aliquot contains ~1 X 106 cells). Cell lysate was sonicated to shear DNA into fragments 200 and 
1000 base pairs length, while keeping the samples on ice (Branson Digital Sonifier, 30 % power, 
10 seconds pulse 3X, 1 minute interval between each pulse). After sonication, samples were 
centrifuged for 10 minutes at 13,000 rpm and 40C, cell supernatant was diluted 10 times in ChIP 
Dilution Buffer, adding protease inhibitors as above. This is done by adding 1800μl ChIP 
Dilution Buffer to the 200μl sonicated cell supernatant. 1% (20μL) of diluted supernatant is 
stored at -200C, this is considered as INPUT, acts as a loading control. To reduce nonspecific 
background, 80μl of Salmon Sperm DNA/Protein A Agarose-50% Slurry was added to 2ml 
diluted cell supernatant and incubated for I hour at 4ºC with agitation. Brief centrifugation (1000 
rpm, 1 min at 40C) was performed to pellet the agarose and the supernatant fraction was 
collected. Immunoprecipitations were performed by incubating the supernatant fractions with 
anti- H3K27Me3 (Active Motif, Carlsbad, CA, 1:200 dilution) or control IgG antibodies for 
overnight at 4ºC with rotation. 60μl of Salmon Sperm DNA/Protein A Agarose Slurry was added 
to the immunoprecipitated complex and incubated for one hour at 40C with rotation to collect the 
antibody/histone complex. Protein A agarose /antibody/histone complexes were collected by 
brief centrifugation, these complexes were washed for 3 min on a rotating platform with 1 ml 
each of the following buffers listed in the order as:  
1. Low Salt Immune Complex Wash Buffer, one wash 
2. High Salt Immune Complex Wash Buffer, one wash 
3. LiCl Immune Complex Wash Buffer, one wash 
4. 1X Tris-EDTA Buffer, two washes 
After each wash, complexes were centrifuged at 1000 rpm for 1 min at 4ºC. Histone 
complexes were eluted from the antibody by incubating with 250μL freshly prepared elution 
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buffer (1%SDS, 0.1M NaHCO3) for 15 min at room temperature (RT). Supernatant fraction was 
collected after centrifugation at 13000 rpm for 5 min at RT. The elution process was repeated 
and eluates were combined (500μL). INPUTS as well as eluates were reverse crosslinked by 
treating with 20μL 5M NaCl at 650C for overnight. Finally, Polymerase Chain Reaction (PCR) 
was performed with primers designed from the sequence of the miR-31 promoter (5’- 
GCTATCTCAACCCACTCTCCGCCT-3’ and 5’-GATTAGATGCTGATGTGAGTGCTG-3’), 
covering a ~200 bp fragment that is upstream of the transcription start site of the miR-31 gene. 
1.3.15. Crystal Violet Staining 
The cells were treated with various doses of mocetinostat or the same doses of vorinostat 
for 72h. The colonies were fixed with paraformadehayde and stained with 0.05% Crystal Violet. 
1.3.16. Human Prostate Cancer Specimens 
Frozen specimens of human prostate cancer tissue and paired normal prostate tissues 
were obtained from 8 patients at Mayo Clinic SPORE, and approved by the Mayo Clinic 
Institutional Review Board. These patients had biopsy-proven prostate cancer and were treated at 
the Mayo Clinic by radical retropubic prostatectomy between January 1995 and December 1998 
without neoadjuvant therapy [43]. Samples were frozen in liquid nitrogen and stored at -80 o C 
until use. Total RNA was isolated from frozen samples, and quantified by real-time PCR. 
1.3.17. Statistical Analysis  
Differences between the mean values were analyzed for significance using the unpaired 
two-tailed Student’s test for independent samples; P 0.05 was considered to be statistically 
significant. 
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CHAPTER 2. POLYCOMB PROTEIN EZH2 SUPPRESSES 
APOPTOSIS BY COORDINATING THE SILENCING OF 
PRO-APOPTOTIC MIR-205 AND MIR-31 
The working hypothesis for Project 1 was that EZH2 contributes to apoptosis resistance 
by integrating DNA methylation-mediated miR-205 silencing with histone methylation-mediated 
silencing of miR-31. The following experiments were performed to prove our hypothesis. 
2.1. Results and Discussion 
2.1.1. Determining the Effect of EZH2 on MiR-31 Expression 
We reported previously that miR-31 expression was decreased in prostate cancer cells, 
resulting in resistance to apoptosis (Bhatnagar N, Li X, Padi SK, et al., 2010). It was recently 
shown that in adult T cell leukemia (Yamagishi M, Nakano K, et al., 2012), the polycomb 
repressive complex can be recruited to the miR-31 promoter (on chromosome 9q21) by 
transcription factor YY1. Subsequently, EZH2 increases trimethylated H3K27 and suppresses 
miR-31 expression (Yamagishi M, Nakano K, et al., 2012). To understand the mechanism of 
miR-31 silencing in prostate cancer, we examined if miR-31 is suppressed by EZH2. We found 
that siRNA knockdown of EZH2 restored miR-31 expression in PC-3 cells (Figure 1A and 1B) 
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Figure 7. EZH2 suppresses miR-31 expression in PC-3 prostate cancer cell line. (A and B) PC-3 
cells were transfected with the negative control or EZH2 targeting siRNAs for 48h. (A) Cell 
lysates were analyzed by western blot using the indicated antibodies. (B) Total RNA was isolated 
from the cells and real-time PCR analysis was performed as described in Materials and Methods. 
All experiments have been repeated three times, and data shown are mean values±S.D. 
Similarly, depletion of EZH2 with DZNep (a known EZH2 inhibitor 27) increased 
miR-31 expression in PC-3 cells and decreased E2F6 (Figure 8A and 8B).  
   
Figure 8. DZNep treatment suppresses miR-31 expression. (A) PC-3 cells were treated with 5 μM 
of DZNep for 24 h. Cell lysates were analyzed by western blot using the indicated antibodies. (B) 
Total RNA was isolated from the cells and real-time PCR analysis was performed. All experiments 
have been repeated three times, and data shown are mean values±S.D. 
 In another prostate cancer cell line DU-145, we also observed that siRNA knockdown of 
EZH2 or DZNeP treatment increased miR-31 expression and decreased E2F6 (Figure 9A and 
9B). 
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Figure 9. EZH2 suppresses miR-31 expression in DU-145 prostate cancer cell line. (A and B) Left, 
DU-145 cells were transfected with negative control or EZH2 targeting siRNAs for 48h. Right, 
DU-145 cells were treated with 5 μM of DZNep for 24 hours. (A) Cell lysates were analyzed by 
western blot using the indicated antibodies. (B) Total RNA was isolated from the cells and 
real-time PCR analysis was performed as described in Materials and Methods. All experiments 
have been repeated three times, and data shown are mean values±S.D. 
2.1.2. EZH2 Regulates Histone Methylation on the MiR-31 Promoter 
We performed 5’ RACE experiments to identify the transcription start site and the 
promoter for the miR-31 gene. The gene encoding miR-31 is located on chromosome 9p21. The 
transcription start site for miR-31 was identified (Figure 10A). To determine if EZH2 regulates 
histone H3K27 methylation, we performed chromosome immunoprecipitation (ChIP) assay near 
the transcription start site (~360 bp upstream) on the miR-31 promoter. Chromatin 
immunoprecipitation assay was performed using the Chromatin Immunoprecipitation (ChiP) 
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Assay Kit (Upstate, Temecula, CA, USA) by following the manufacturer’s protocol. 
Immunoprecipitations were performed using anti-dimethyl-histone H3 lysine 27 (H3K27Me3), 
and control IgG antibodies. Using ChIP assay followed by a PCR analysis, we measured the 
H3K27Me3 levels on the promoter region of miR-31 in EZH2 knockdown or EZH2 depleted 
PC-3 prostate cancer cells. As shown in Figure 10 (B and C), siRNA knockdown of EZH2 or 
DZNep treatment decreased the levels of H3K27 trimethylation on promoter of miR-31.  
  
Figure 10. EZH2 regulates H3K27 methylation on the miR-31 promoter. (A) The putative 
transcription start site (indicated by +1) and genomic sequence of the miR-31 gene is shown. The 
mature miR-31 sequence is indicated by “→”. The DNA fragment covered by ChIP assay is 
indicated by “−“. The locations of the first four exons on the chromosomes were indicated. (B) 
PC-3 cells were transfected with the negative control or EZH2 targeting siRNAs for 48h. ChIP 
assay was performed as described in Materials and Methods, using primers specific for the miR-31 
promoter and the indicated antibodies. (C) PC-3 cells were treated with 5 M of DZNep for 24 
hours. ChIP assay was performed as in (B). 
ChIP assay at 1250 bp upstream from the transcription start site did not detect H3K27 
methylation, indicating that methylation occurs specifically at the transcription start site. As 
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shown in Figure 11, siRNA knockdown of EZH2 decreased the binding of EZH2 to the miR-31 
promoter, while the levels of histone H3 on the promoter were not changed by EZH2 knockdown. 
 
Figure 11. EZH2 regulates H3K27 methylation specifically at the transcription start site. PC-3 
cells were transfected with the negative control or EZH2 targeting siRNAs for 48h. ChIP assay 
was performed as described in Materials and Methods, using primers specific for the miR-31 
promoter and the indicated antibodies. The experiments have been repeated three times. 
2.1.3. Downregulation of EZH2 Increases Docetaxel-induced Apoptosis in Prostate 
Cancer Cells 
As miR-31 regulates apoptosis by targeting the anti-apoptotic protein E2F6 (Bhatnagar N, 
Li X, et al., 2010), we hypothesized that by silencing miR-31, EZH2 may regulate apoptosis in 
prostate cancer cells. We transfected PC-3 cells with the negative control or EZH2 targeting 
siRNAs and treated the cells with docetaxel, a drug used clinically to treat prostate cancer. EZH2 
knockdown increased miR-31 expression with or without Docetaxel treatment in PC-3 and 
DU-145 prostate cancer cell lines (Figure 12).  
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Figure 12. EZH2 regulates apoptosis in PC-3 prostate cancer cells. PC-3 cells were transfected 
with the negative control or EZH2 targeting siRNAs. At 24h after siRNA transfection, cells were 
treated with 10 nM docetaxel for additional 24h. Total RNA was isolated from the cells and 
real-time PCR analysis was performed as described in Materials and Methods. The experiments 
have been repeated three times, data shown are mean values + SD. 
Docetaxel was able to induce higher level of apoptosis in cells that were transfected with 
EZH2 siRNA, compared to cells that were transfected with the negative control siRNA (Figure 
13A,B). Higher levels of active (cleaved) caspase-3 and caspase-9, as well as PARP cleavage, 
were observed in cells after EZH2 siRNA transfection and docetaxel treatment (Figure 13C).  
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Figure 13. EZH2 knockdown increases docetaxel-induced apoptosis in PC-3 prostate cancer cells. 
PC-3 cells were transfected with the negative control or EZH2 targeting siRNAs. At 24 h after 
siRNA transfection, cells were treated with 10 nM docetaxel for additional 24 h. (A) Cell lysates 
were analyzed by western blot using the indicated antibodies. (B) Apoptosis was measured by Cell 
Death Detection ElisaPLUS analysis as described in Materials and Methods. (C) Western blotting 
was performed with the antibodies indicated. The experiments have been repeated three times, and 
data shown are mean values±S.D. 
In DU-145 cells, we also observed that siRNA knockdown of EZH2 increased miR-31 
expression (Figure 14A), docetaxel-induced apoptosis, as well as active caspase-3/caspase-9, and 
PARP cleavage (Figure 14B and 14C). 
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Figure 14. EZH2 knockdown increases docetaxel-induced apoptosis in DU-145 prostate cancer 
cells. (A) DU-145 cells were transfected with the negative control or EZH2 targeting siRNAs. At 
24h after siRNA transfection, cells were treated with 10 nM docetaxel for additional 24h. Total 
RNA was isolated from the cells and real-time PCR analysis was performed as described in 
Materials and Methods. (B) Apoptosis was measured by Cell Death Detection ElisaPLUS analysis 
as described in Materials and Methods. (C) Western blotting was performed with the indicated 
antibodies. The experiments have been repeated three times, data shown are mean values + SD. 
 
 
2.1.4. Overexpression of EZH2 Confers Resistance to Docetaxel-induced Apoptosis 
We expressed EZH2 exogenously to determine if EZH2 can contribute to apoptosis 
resistance in prostate cancer cells. We transfected PC-3 cells with pCEP4-EZH2 expression vector 
to overexpress Flag-tagged EZH2 protein. Overexpression of EZH2 was confirmed by western 
blotting (Figure 15A). As expected, overexpression of EZH2 suppressed miR-31 (Figure 15B), 
and increased E2F6 protein (Figure 15A). When treated with docetaxel, cells expressing EZH2 
were significantly more resistant to drug-induced apoptosis, comparing to empty 
vector-transfected cells (Figure 15C).  
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Figure 15. EZH2 confers resistance to docetaxel-induced apoptosis. PC-3 cells were transfected 
with the empty expression vector or pCEP4-EZH2. At 24h after transfection, cells were treated 
with 10 nM of docetaxel for additional 24h. (A) EZH2 and E2F6 expression was determined by 
western blot. (B) Total RNA was isolated from the cells and real-time PCR analysis was 
performed. (C) Apoptosis was measured by Cell Death Detection ElisaPLUS analysis. The 
experiments have been repeated three times, data shown are mean values + SD. 
2.1.5. SiRNA Knockdown of E2F6 Sensitizes Prostate Cancer Cells to Docetaxel-induced 
Apoptosis 
We have previously shown that miR-31 targets E2F6 (Bhatnagar N, Li X, et al., 2010). 
E2F6 is an anti-apoptotic protein that inhibits UV- and hypoxia-induced apoptosis (Yang WW, 
Wang ZH, et al., 2007; Yang WW, Shu B, et al., 2008). To determine the effects of E2F6 on 
chemotherapy-induced apoptosis in prostate cancer cells, we used siRNA to specifically 
knockdown E2F6 in PC-3 cells. As shown in Figure 16A, transfection of E2F6 targeting siRNA 
was able to decrease levels of E2F6 protein. SiRNA knockdown of E2F6 sensitized PC-3 cells to 
apoptosis induced by docetaxel (Figure 16B).   
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Figure 16. SiRNA knockdown of E2F6 sensitizes PC-3 cells to docetaxel-induced apoptosis. PC-3 
cells were transfected with the negative control or E2F6 targeting siRNAs. At 24h after siRNA 
transfection, cells were treated with 10 nM docetaxel for additional 24h. (A) Cell lystates were 
analyzed by western blotting with the indicated antibodies. (B) Apoptosis was measured by Cell 
Death Detection ElisaPLUS analysis. The experiments have been repeated three times, data shown 
are mean values + SD. 
In DU-145 cells, we also observed that siRNA knockdown of E2F6 increased 
docetaxel-induced apoptosis (Figure 17).  
 
Figure 17. SiRNA knockdown of E2F6 sensitizes DU-145 cells to docetaxel-induced apoptosis. 
DU-145 cells were transfected with the negative control or E2F6 targeting siRNAs. At 24h after 
siRNA transfection, cells were treated with 10 nM docetaxel for additional 24h. (A) Cell lystates 
were analyzed by western blotting with the indicated antibodies. (B) Apoptosis was measured by 
Cell Death Detection ElisaPLUS analysis. The experiments have been repeated three times, data 
shown are mean values + SD. 
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In both PC-3 and DU-145 cells, miR-31 levels were not affected by E2F6 knockdown or 
docetaxel treatment (Figure 18). 
 
Figure 18. Real-Time PCR results confirming miR-31 expression levels after E2F6 knockdown 
and docetaxel treatment. PC-3 cells (A) and DU-145 cells (B) were transfected with the negative 
control or E2F6 targeting siRNAs. At 24h after siRNA transfection, cells were treated with 10 nM 
docetaxel for additional 24h. Total RNA was isolated from the cells and real-time PCR analysis 
was performed as described in Materials and Methods. The experiments have been repeated three 
times, data shown are mean values + SD. 
2.1.6. MiR-205 Regulates MiR-31 through EZH2 
We have reported that miR-205 is silenced in prostate cancer by promoter 
hypermethylation (Bhatnagar N, Li X, et al., 2010). Interestingly, miR-205 has been shown to 
decrease EZH2 protein in prostate cancer cells (Gandellini P, Folini M, et al., 2009). We 
hypothesized that the epigenetic silencing of miR-205 (through promoter methylation) will lead to 
increased expression of EZH2, which in turn epigenetically represses miR-31 expression through 
histone methylation. To test our hypothesis, we examined the effects of miR-205 on miR-31 
expression. As shown in Figure 19A, blocking miR-205 with an anti-miR inhibitor in 
WPE1-NA22 cells (a cell line that expresses high levels of endogenous miR-31 (Bhatnagar N, Li 
X, et al., 2010)) decreased miR-31 expression, and increased EZH2 and E2F6 proteins. In contrast, 
overexpression of miR-205 in PC-3 cells caused a decrease of EZH2 and an increase of miR-31, 
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which in turn decreased E2F6 (Figure 19B). (The experiences were performed by Sathish Kumar 
Padi)  
 
Figure 19. EZH2 integrates miR-205 silencing and miR-31 suppression. (A). WPE1-NA22 cells 
were transfected with negative control or anti-miR-205 inhibitor. After 48 h, total RNA and 
protein were collected and miR-31 expression was analyzed by real-time PCR and western blots 
were carried out using indicated antibodies. (B). PC-3 cells were transfected with the negative 
control miR or miR-205 for 48 h, and real-time PCR and western blots were performed as in (A). 
The experiments have been repeated three times, and data shown are mean values±S.D. 
2.1.7. MiR-205, EZH2, and MiR-31 Expression in Human Prostate Cancer Specimens 
We analyzed miR-205, EZH2, and miR-31 expression in eight pairs of human prostate 
cancer specimens and the adjacent non-malignant tissues using real-time PCR. We found that 
miR-205 and miR-31 expression levels were decreased in the cancer samples comparing to the 
normal tissues (Figure 20). In the meantime, EZH2 expression was increased in the cancer 
specimens. Interestingly, the expression levels of miR-205, EZH2, and miR-31 correlate well 
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among the individual patients (Pearson's correlation coefficient test: R= -0.7911 between the 
levels of EZH2 and miR-31; R= -0.6236 between EZH2 and miR-205). For example, low levels of 
miR-205 in patients PR2647 and PR1107 match the high levels of EZH2 in the same patients, 
which in turn lead to the very low levels of miR-31 in these patients. This observation supports our 
hypothesis that EZH2 may coordinate the silencing of miR-205 and miR-31 in prostate cancer. 
 
Figure 20. MiR-205, EZH2, and miR-31 expression in human prostate cancer specimens. Total 
RNAs were isolated from eight pairs of prostate cancer specimens and the adjacent normal 
prostate tissues. (Each pair of samples were from the same patient indicated by the patient ID on 
the X axis.) MiRNA and EZH2 expression were determined by real-time PCR. The ratios of 
miR-205 (A), EZH2 (B), and miR-31 (C) levels in the tumor samples versus that in the matched 
adjacent non-tumor samples were shown (the expression levels in each normal tissue were 
designated as 1)     
2.2. Discussion 
Overexpression of EZH2 is found in various types of solid tumors such as melanoma 
(Asangani IA, Harms PW, et al., 2012), breast cancer (Kleer CG, Cao Q, et al., 2003), cervical 
cancer (Holland D, Hoppe-Seyler K, et al., 2008), gastric cancer (Matsukawa Y, Semba S, et al., 
2006), and prostate cancer (Varambally S, Dhanasekaran SM, et al., 2002). High levels of EZH2 
are linked to tumor growth, metastasis, and poor prognosis for cancer patients. EZH2 suppresses 
apoptosis in a variety of cancers, including gastric cancer (Xie L, Zhang Z, et al., 2014), bladder 
cancer (Wang Y, Xiang W, et al., 2014), leukemia (Zhou J, Bi C, et al., 2011), and prostate 
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cancer (Li K, Liu C, et al., 2013). However, the mechanisms of apoptosis suppression by EZH2 
remain poorly understood. It has been reported that miR-205 suppresses EZH2 expression 
(Gandellini P, Folini M, et al., 2009) in prostate cancer cells and miR-205 promotes apoptosis 
(Bhatnagar N, Li X, et al., 2010; Verdoodt B, Neid M, et al., 2013). In this study, we identified a 
novel mechanism of EZH2 regulation of apoptosis in prostate cancer. We propose that EZH2 
coordinates the silencing of the pro-apoptotic miR-205 and miR-31. Thus, DNA 
methylation-mediated silencing of miR-205 (Bhatnagar N, Li X, et al., 2010) can lead to histone 
methylation-mediated silencing of miR-31, with EZH2 as the coordinator of the two separate 
events. As a result, the expression of anti-apoptotic protein E2F6 is increased and contributes to 
the development of apoptosis resistance. It has been reported that the genomic loss of miR-101 
can result in the up-regulation of EZH2 in prostate cancer (Varambally S, Cao Q, et al., 2008) 
and miR-101 promote apoptosis in cancer cells (Wang Y, Xiang W, et al., 2014; Xu Y, An Y, et 
al., 2013). EZH2 may also contribute to apoptosis resistance by linking the genomic loss of 
miR-101 to miR-31 silencing. 
At present, we do not know the mechanism of how miR-205 inhibits EZH2. There is no 
target sequence of miR-205 within the 3’ UTR of EZH2 gene (www.targetscan.org). Thus, 
miR-205 may suppress EZH2 indirectly through its action on molecules that control EZH2 
expression. For example, the oncogene Myc can regulate EZH2 at both transcriptional and 
post-transcriptional levels (Koh CM, Iwata T, et al., 2011). Furthermore, overexpression of ERG 
(as a result of fusion between the TMPRESS2 and ERG from chromosome 21 translocation) can 
directly activate EZH2 (Yu J, Mani RS, et al., 2010). Epigenetic silencing of miR-205 may result 
in the increase of these EZH2 activators, which in turn increases EZH2 expression. 
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While a previous study has reported promoter methylation of the miR-31 gene (Lin PC, 
Chiu YL, et al., 2013), the methylation analysis was done in the region of the CpG island that is 
located in the intron region between exons 1 and 2 (Figure 2A).  The CpG island is about 32 kb 
away from the transcription start site that we identified with 5’RACE. Our ChIP assay was 
performed in the revised promoter region that has no CpG island (Figure 2), indicating that 
EZH2 may suppress miR-31 expression independent of DNA methylation. Previously, it has 
been shown that histone H3K27 trimethylation can silence the expression of miR-22 independent 
of promoter methylation (Lin PC, Chiu YL, et al., 2009).  
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CHAPTER 3. HDAC INHIBITOR MOCETINOSTAT INDUCES 
APOPTOSIS BY INCREASING MIR-31 EXPRESSION AND 
SUPPRESSION OF E2F6 
The working hypothesis for Project 2 was that mocetinostat might be able to activate 
miR-31 and downregulation of E2F6, and consequently induce apoptosis in prostate cancer. The 
following experiments were performed to prove our hypothesis. 
3.1. Results and Discussion 
3.1.1. Mocetinostat Induces Apoptosis in Prostate Cancer Cells  
We determined if mocetinostat can induce apoptosis in prostate cancer cells. As shown in 
Figure 21A, mocetinostat induced significant levels of apoptosis in DU-145 cells in a 
dose-dependent manner. Induction of apoptosis was determined by the cell death ELISA assay 
measuring mono- and oligonucleosomes in the lysates of apoptotic cells. Similarly, mocetinostat 
also induced significant levels of apoptosis in PC-3 cells (Figure 21B). We compared the 
antitumor activities of mocetinostat and vorinostat (suberanilohydroxamic acid, SAHA) (P.A. 
Marks 2007), a FDA-approved non-selective HDAC inhibitor. Mocetinostat was significantly 
more potent than vorinostat in prostate cancer suppression (Figure 21C). 
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Figure 21. Mocetinostat induces apoptosis in prostate cancer cells. DU-145 cells. (A) and PC-3 
cells (B) were treated with various doses of mocetinostat for 24 hours and apoptosis was analyzed 
using the Cell Death Detection ElisaPLUS kit as described in Materials and Methods. (C) DU-145 
cells were treated with various doses of mocetinostat or vorinostat for 72 hours. The colonies were 
fixed with paraformaldehyde and stained with 0.05% Crystal Violet. All experiments have been 
repeated three times, data shown are mean values + SD.2.9.  
3.1.2. Mocetinostat Induces MiR-31 Expression and Downregulates E2F6 
We recently demonstrated that the downregulation of miR-31 contributes to apoptosis 
resistance in prostate cancer cells (N. Bhatnagar, X. Li, et al., 2010). Since miR-31 is repressed 
by epigenetic mechanisms in prostate cancer (P.C. Lin, Y.L. Chiu, et al., 2013), we hypothesized 
that mocetinostat may activate miR-31 expression. The effects of mocetinostat on miR-31 
expression were determined by real-time PCR. As shown in Figure 22A, mocetinostat 
significantly induced miR-31 expression. We have previously shown that miR-31 targets E2F6 
(N. Bhatnagar, X. Li, et al., 2010), which is a potent anti-apoptotic protein that can inhibit UV- 
and hypoxia-induced apoptosis (W.W. Yang, Z.H. Wang, et al., 2007; W.W. Yang, B. Shu, et al., 
2008). As a result of miR-31 induction, mocetinostat significantly decreased E2F6 protein in 
DU-145 cells (Figure 22B).  
 46 
 
Figure 22. Mocetinostat activates miR-31 expression in prostate cancer cells. (A) DU-145 cells 
were treated with 5 µM mocetinostat for 24h. Total RNA was isolated from untreated (control) and 
mocetinostat-treated cells and real-time PCR analysis was performed as described in Materials and 
Methods. (B) DU-145 cells were treated with various doses of mocetinostat for 24h. Western 
blotting was performed with anti-E2F6 and anti-tubulin antibodies. The experiments have been 
repeated three times, data shown are mean values + SD. 
To further understand the mechanism of mocetinostat-induced apoptosis, we determined 
the effects of mocetinostat on the expression of pro-apoptotic members of Bcl-2 family proteins 
(N.N. Danial, S.J. Korsmeyer, et al,. 2007). Interestingly, Bad was significantly increased by 
mocetinostat treatment while the expression levels of other proteins were either reduced (Puma, 
Bid, and Bax) or unchanged (Bak) (Figure 23A). Since Bad is a key pro-apoptotic protein that 
triggers the intrinsic pathway of apoptosis (P. Jiang, W. Du,et al., 2007; N.N. Danial 2008), we 
examined the effects of mocetinostat on the caspases. As shown in Figure 23B, mocetinostat 
treatment significantly increased the levels of activated (cleaved) caspase-9 and caspase-3. The 
cleaved products of PARP, substrates of the caspases, were also increased by mocetinostat. 
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Figure 23. The expression levels of pro-apoptotic members of the Bcl-2 family proteins and 
caspases proteins after treatment of mocetinostat. (A and B) DU-145 cells were treated with 
various doses of mocetinostat for 24h. Western blotting was performed with the indicated 
antibodies. 
3.1.3. E2F6 Regulates Mocetinostat-induced Apoptosis in Prostate Cancer Cells  
To determine the role of E2F6 in mocetinostat-induced apoptosis, we used siRNA to 
knockdown E2F6 in DU-145 cells. As shown in Figure 24A, E2F6 protein expression was 
significantly reduced by siRNA treatment. Knockdown of E2F6 sensitized DU-145 cells to 
apoptosis induced by mocetinostat (Figure 24B). We also expressed E2F6 exogenously to 
determine if E2F6 can contribute to apoptosis resistance in prostate cancer cells. Overexpression 
of E2F6 was confirmed by western blotting (Figure 24C). When treated with mocetinostat, 
DU-145 cells overexpressing E2F6 were significantly more resistant to drug-induced apoptosis, 
comparied to empty vector-transfected cells (Figure 24D).  
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Figure 24. E2F6 regulates mocetinostat-induced apoptosis. (A) DU-145 cells were transfected 
with the negative control or E2F6 targeting siRNAs. At 48h after siRNA transfection, cell lystates 
were analyzed by western blotting with the indicated antibodies. (B) DU-145 cells were 
transfected with the negative control or E2F6 siRNAs. At 24h after siRNA transfection, cells were 
treated with 1 µM mocetinostat for additional 24h. Apoptosis was measured by Cell Death 
Detection ElisaPLUS analysis as described in Materials and Methods. (C) DU-145 cells were 
transfected with the empty expression vector or pcDNA3-HA-E2F6. At 24h after transfection, 
E2F6 overexpression was confirmed by western blot. (D) DU-145 cells were transfected with the 
empty expression vector or pcDNA3-HA-E2F6. At 24h after transfection, cells were treated with 5 
µM of mocetinostat for additional 24h and apoptosis was measured by Cell Death Detection 
ElisaPLUS analysis as described in Materials and Methods. The experiments have been repeated 
three times, data shown are mean values + SD. 
3.1.4. Mocetinostat Induces MiR-31 Expression and Activates Apoptosis in Primary 
Prostate Cancer Stem Cells 
It is postulated that cancer stem cells mediate tumor formation, metastasis, and resistance 
to chemotherapy (B. Sharpe, M. Beresford, et al,. 2013). We tested if mocetinostat is effective 
against prostate cancer stem cells. As shown in Figure 25A, mocetinostat induced significant 
levels of apoptosis in patient-derived primary prostate cancer stem cells. Furthermore, 
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mocetinostat increased miR-31 expression (Figure 25B), and decreased E2F6 protein (Figure 
25C) in prostate cancer stem cells. The level of pro-apoptotic protein Bad was increased by 
mocetinostat (Figure 25C).  
 
Figure 25. Mocetinostat induces apoptosis in the primary prostate cancer stem cells. (A) Prostate 
cancer stem cells were treated with various doses of mocetinostat for 24 hours and apoptosis was 
analyzed using the Cell Death Detection ElisaPLUS kit. (B) Prostate cancer stem cells were treated 
with 5 µM mocetinostat for 24h. Total RNA was isolated and real-time PCR analysis was 
performed as described in Materials and Methods. (C) Prostate cancer stem cells were treated with 
5 uM of mocetinostat for 24h. Western blotting was performed with the indicated antibodies. The 
experiments have been repeated three times, data shown are mean values + SD. 
3.2. Discussion 
Mocetinostat is a class I selective HDAC inhibitor and has promising antitumor activities 
in preclinical studies (M. Fournel, C. Bonfils, et al., 2008; C. Bonfils, A. Kalita, et al., 2008). 
More importantly, recent clinical trials have demonstrated excellent response of mocetinostat 
against myelodysplastic syndrome and relapsed Hodgkin's lymphoma, with acceptable safety 
profiles (S.M. Luger, C.L. O'Connell, et al., 2013; A. Younes, Y. Oki, et al., 2011). However, a 
phase II study also found that mocetinostat has limited efficacy as a single agent in relapsed and 
refractory chronic lymphocytic leukemia (CLL) (K.A. Blum, A. Advani, et al., 2009). Thus, it is 
important to understand the mechanism of mocetinostat-induced apoptosis in order to improve its 
efficacy in cancer therapy and overcome drug resistance. Our findings in this report serve this 
purpose by helping to understand the molecular basis of mocetinostat-induced apoptosis. We 
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have previously shown that in prostate cancer cell lines derived from advanced metastatic 
cancers, miR-31 is downregulated to contribute to the resistance to chemotherapy-induced 
apoptosis (N. Bhatnagar, X. Li, et al., 2010). Here, we have demonstrated that mocetinostat 
activates the expression of miR-31 which in turn decreases expression of the anti-apoptotic 
protein E2F6. We also found that mocetinostat increases the expression of pro-apoptotic protein 
Bad. Our data have established a mechanistic model to explain how mocetinostat induces 
apoptosis in prostate cancer (Figure 4D). By inducing miR-31 to decrease E2F6 while in the 
meantime increasing Bad, mocetinostat tipped the balance between the anti-apoptotic and 
pro-apoptotic proteins (S.N. Willis, J.M. Adams, et al., 2005), resulting in increased apoptosis. 
Evidence is emerging that the prostate cancer stem cells may play important roles in 
resistance to castration (M. Germann, A. Wetterwald, et al., 2012) and chemotherapy (B. Sharpe, 
M. Beresford, et al., 2013). Recently, it has been shown that mocetinostat induces cell cycle 
arrest and apoptosis in colon cancer initiating cells (S. Sikandar, D. Dizon, X. Shen, et al., 2010). 
Our data suggest that mocetinostat can efficiently induce apoptosis in the primary prostate cancer 
stem cells, through a mechanism involving miR-31 and E2F6 (Figure 4). Thus, mocetinostat is 
an effective drug for eliminating the prostate cancer stem cells. 
Azacitidine can activate the expression of epigenetically silenced genes by inhibiting 
DNA promoter methylation (K. O'Dwyer, P. Maslak, et al., 2008). Moreover, recent clinical 
trials have demonstrated excellent results when azacitidine and mocetinostat are used together in 
cancer therapy (S.M. Luger, C.L. O'Connell, et al., 2013). It will be interesting to test if 
azacitidine can act with mocetinostat synergistically to activate miR-31 and induce apoptosis in 
prostate cancer cells, since the two drugs target different mechanisms of miR-31 silencing. 
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CHAPTER 4. SUMMARY AND CONCLUSIONS; CLINICAL 
IMPLICATIONS AND FUTURE DIRECTIONS 
4.1. Summary and Conclusions 
4.1.1. Polycomb Protein EZH2 Suppresses Apoptosis by Silencing the Proapoptotic  
MiR-31 
Dysregulation of various miRNAs has been shown to have critical roles in cancer biology, 
ranging from proliferation, differentiation, metabolism, metastasis, to apoptosis (N. Bhatnagar, X. 
Li, et al., 2010). Our previous studies have shown that miR-205 and miR-31 are the two of the 
most significantly downregulated microRNAs in prostate cancer. And miR-205 undergoes 
downregulation by DNA methylation-mediated silencing on the promoter region. However the 
mechanism for downregulation of miR-31 in prostate cancer is still elusive. In the light of the 
recent demonstration that the polycomb repressor complex 2 (PRC2) can be recruited to the 
miR-31 promoter region by transcription factor YY1 in adult T-cell leukemia. Moreover, the 
polycomb protein EZH2 of the PCR2 increases trimethylated H2K27 to suppress miR-31 
expression (Makoto Yamagishi, Kazumi Nakano 2012). EZH2 has also been found to be 
extensively overexpressed in metastatic prostate cancer (Varambally S, Dhanasekaran SM, 2002). 
Therefore, we proposed the hypothesis that miR-31 is epigenetically suppressed by polycomb 
protein EZH2 in prostate cancer. EZH2 suppresses apoptosis in a variety of cancers, including 
gastric cancer, bladder cancer, leukemia, and prostate cancer. However, the mechanisms of 
apoptosis suppression by EZH2 are still poorly understood. Our previous studies have identified 
an anti-apoptotic protein E2F6 as the target of miR-31; and downregulation of miR-31 can confer 
resistance to chemotherapy induced apoptosis. Based on these findings, we hypothesized that 
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EZH2 can suppresses apoptosis though decreasing miR-31 expression, and consequently cause 
upregulation of anti-apoptotic protein E2F6 expression. Interestingly, miR-205 has been shown to 
decrease EZH2 protein in prostate cancer cells. We hypothesized that the epigenetic silencing of 
miR-205 (through promoter methylation) will lead to increased expression of EZH2 which in turn 
epigenetically represses miR-31 expression through histone methylation. 
Our results showed that EZH2 suppresses miR-31 expression by trimethylation of Histone 
3 lysine 27 on the promoter region. SiRNA knockdown of EZH2 increased miR-31 expression, 
and consequently decreased E2F6 expression in PC-3 cells, resulting in the sensitization of 
prostate cancer cells to docetaxel-induced apoptosis. Conversely, overexpression of EZH2 
blocked docetaxel-induced apoptosis. We further demonstrated that miR-205 silencing is linked to 
miR-31 silencing through EZH2. Suppression of miR-205 with a miRNA inhibitor caused an 
increase of EZH2 protein, which in turn inhibited miR-31 expression. In the other hand, 
overexpression of miR-205 decreased EZH2 protein and increased miR-31expression. By 
comparing eight pairs of human prostate cancer specimens with the adjacent non-malignant tissues, 
we found that miR-205 and miR-31 expression levels were decreased in the cancer samples. EZH2 
expression was also increased in the cancer specimens, and had a negative correlation with 
miR-205 and miR-31 expression. 
Finally, we have established novel epigenetic mechanisms to illustrate EZH2 coordination 
of miR-205 and miR-31 silencing in the development of apoptosis resistance (Figure 26). This 
study has also identified EZH2 and miR-31 as novel targets for the effective treatment of prostate 
cancer. 
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Figure 26. Schematic illustration of EZH2 coordination of miR-205 and miR-31 silencing in the 
development of apoptosis resistance. The promoter methylation-mediated silencing of miR-205 
leads to the increase of EZH2 expression, which in turn suppresses miR-31 through H3K27 
methylation on the miR-31 promoter. The reduction of miR-31 expression results in the increase of 
anti-apoptotic protein E2F6, which confers resistance to apoptosis. 
4.1.2. HDAC Inhibitor Mocetinostat Induces Apoptosis by Increasing MiR-31 Expression 
and Suppression of E2F6 
The mechanisms involved in epigenetic therapy typically cluster into three categories 
including DNA methylations, histone modifications, and regulatory RNAs (Razin Aharon 1998; 
Strahl, Brian D. 2000; Prasanth Kannanganattu V., David L. 2007). Mocetinostat, also known as 
MGCD103, is one of the class I selective histone deacetylases (HDACs) inhibitor that is developed 
for epigenetic therapy. Although mocetinostat has been shown to effectively kill prostate cancer 
cells, the mechanisms of apoptosis induction remain elusive. Recently, we have reported that 
miR-31 was significantly downregulated in prostate cancer cells and its downregulation resulted in 
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overexpression of anti-apoptotic protein E2F6 and resistance to apoptosis.  Studies by Lin et al 
have shown that miR-31 is epigenetically silenced in prostate cancer by promoter 
hypermethylation and histone H3K27 trimethylation (Lin, P.C., e al. 2013). Since HDACs are 
often involved in DNA methylation-mediated gene silencing (McCabe M.T., J.C. Brandes 2009), 
we tested whether mocetinostat can activate miR-31 expression. Intriguingly, we found that 
mocetinostat significantly induced miR-31 expression in prostate cancer cells and decreased the 
expression of its target, the anti-apoptotic protein E2F6. The expressions of pro-apoptotic protein 
Bad, and activation of caspase-3 and caspase-9 is upregulated by mocetinostat as well. While 
siRNA knockdown of E2F6 sensitized cancer cells to mocetinostat-induced apoptosis, 
overexpression of E2F6 blocked mocetinostat-induced apoptosis. Importantly, we found that 
mocetinostat also increased miR-31 expression, decreased E2F6, upregulated Bad protein, and 
induced apoptosis in the primary prostate cancer stem cells. 
Based on the results presented above, we have established a model to illustrate the role of 
miR-31in mocetinostat-induced apoptosis. Activation of miR-31 and downregulation of E2F6 
contribute to mocetinostat-induced apoptosis in prostate cancer. These findings identified a novel 
mechanism that contributes to mocetinostat-induced apoptosis in prostate cancer. 
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Figure 27. Schematic illustration of the role of miR-31 in mocetinostat-induced apoptosis. By 
inhibiting the class I HDACs, mocetinostat activates miR-31 expression and subsequently 
decreases E2F6. In the meantime, mocetinostat also increases the pro-apoptotic protein Bad. As a 
result, apoptosis is triggered in the prostate cancer cells. 
4.2. Clinical Implications and Future Directions 
 Various small molecule drugs have been developed to target EZH2. For example, 
GSK126 is a very potent EZH2 inhibitor (with a Ki of 0.5–3 nM) and has high selectivity for 
EZH2 (more than 1000-fold higher activity than its activity for 20 other human 
methyltranserases). Importantly, GSK126 inhibits the growth of EZH2 mutant diffuse large 
B-cell lymphoma xenografts in mice (McCab MT, Ott HM 2012). Our findings indicate that 
EZH2 functions as a key coordinator in apoptosis suppression. Targeting EZH2 with drugs like 
GSK126 may not only induce apoptosis by itself but also sensitize cancer cells to other agents of 
chemotherapy.  
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In current clinical trials of mocetinostat and other HDAC inhibitors, HDAC activity 
inhibition and histone acetylation are used as biomarkers to measure pharmacodynamics 
responses. Our findings in this part of study have identified new parameters (miR-31, E2F6, Bad) 
that may be used to monitor tumor response to mocetinostat. These apoptosis regulators may be 
useful to predict how efficiently mocetinostat can kill the prostate cancer cells. 
The future directions of this project include: (a) Synthesis of novel small molecule EZH2 
inhibitors, (b) Systemic delivery of stable and synthetic miR-205 and miR-31. 
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